KQKun Qiao

Kun Qiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kun Qiao has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Shipeng Ning

    Research Center of Nanomedicine Technology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China

    2 shared publications
  • You Pan

    Department of Breast Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning

    2 shared publications
  • Cheng Luo

    Department of Anesthesiology, The Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, China

    1 shared publication
  • Hongbin Wang

    Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China

    1 shared publication
  • Lei Li

    Department of Breast Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning

    1 shared publication
  • Pengyuan Qi

    Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

    1 shared publication

Latest Publications

  • Open Access

    Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer

    by Lei Li, Hongbin Wang, Shiyuan Zhang, Song Gao, Xiuxin Msc Lu, You Pan, Wei Msc Tang, Rong Msc Huang, Kun Qiao, Shipeng Ning

    Background: In recent years, the widespread use of lipid-lowering drugs, especially statins, has attracted people’s attention. Statin use may be potentially associated with a reduced risk of breast cancer. Objective: To explore the relationship between statin use and cancer risk. And further explore the potential role of statins in the adjuvant treatment of breast cancer. Methods: Data for the Mendelian randomization portion of the study were obtained from genome-wide association studies of common cancers in the UK Biobank and FinnGen studies and from the Global Lipid Genetics Consortium’s low density lipoprotein (LDL). In addition, the impacts of statins and chemotherapy drugs on breast cancer were examined using both in vitro and in vivo models, with particular attention to the expression levels of the immune checkpoint protein PD-L1 and its potential to suppress tumor growth. Results: Data from about 3.8 million cancer patients and ~1.3 million LDL-measuring individuals were analyzed. Genetically proxied HMGCR inhibition (statins) was associated with breast cancer risk reduction (P=0.0005). In vitro experiments showed that lovastatin significantly inhibited paclitaxel-induced PD-L1 expression and assisted paclitaxel in suppressing tumor cell growth. Furthermore, the combination therapy involving lovastatin and paclitaxel amplified CD8+ T-cell infiltration, bolstering their tumor-killing capacity and enhancing in vivo efficacy. Conclusion: The utilization of statins is correlated with improved prognoses for breast cancer patients and may play a role in facilitating the transition from cold to hot tumors. Combination therapy with lovastatin and paclitaxel enhances CD8+ T-cell activity and leads to better prognostic characteristics.


  • Self-cascade catalytic single-atom nanozyme for enhanced breast cancer low-dose radiotherapy

    by Pengyuan Qi, Cheng Luo, You Pan, Shuaijie Ding, Xiang Li, Kun Qiao, Shipeng Ning